v3.23.2
CONDENSED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue:        
Total revenue $ 6,933 $ 23,003 $ 13,098 $ 27,793
Operating expenses:        
Cost of goods sold 1,418   4,008 2,081
Research and development 30,310 19,905 54,644 41,178
General and administrative 7,545 7,570 14,436 16,917
Total operating expenses 39,273 27,475 73,088 60,176
Operating loss (32,340) (4,472) (59,990) (32,383)
Other income, net 861 266 1,846 428
Net loss $ (31,479) $ (4,206) $ (58,144) $ (31,955)
Net loss per share:        
Basic $ (0.58) $ (0.08) $ (1.08) $ (0.60)
Diluted $ (0.58) $ (0.08) $ (1.08) $ (0.60)
Weighted average shares:        
Basic 54,002,988 53,614,668 53,937,875 53,561,161
Diluted 54,002,988 53,614,668 53,937,875 53,561,161
Other comprehensive income (loss), net of tax of $0:        
Change in unrealized gains (losses) on available-for-sale marketable securities $ 371 $ (324) $ 942 $ (1,689)
Total comprehensive loss (31,108) (4,530) (57,202) (33,644)
Collaborative revenue        
Revenue:        
Total revenue 5,410 8,003 8,160 8,003
Commercial supply revenue        
Revenue:        
Total revenue 1,400   4,591 4,790
Royalty revenue        
Revenue:        
Total revenue $ 123   248  
License and milestone fees        
Revenue:        
Total revenue   $ 15,000   $ 15,000
Clinical compound revenue        
Revenue:        
Total revenue     $ 99